Company Profile
Immuron Limited, a biopharmaceutical company provides the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. Its business is organized into two segments, R&D; and Hyper-immune Products.
The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection
Protectyn, an immune supplement to help maintain a healthy digestive function and liver. It also develops Travelan (IMM-124E), which is in Phase II clinical trial, to reduce the risk of contracting travelers' diarrhea
IMM-529, which is in Phase II clinical trial, for treating patients suffering from recurring clostridium difficile infection. In additon, the company develops IMM-986, that is in pre-clinical stage, as well as technology platform.
The company has a collaboration with the US Naval Medical Research Command and Silver Spring, MD, USA to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections
A research collaboration with the Walter Reed Army Institute of Research to develop three Shigella-specific therapeutic products. Incorporated in 1994 and headquartered in Carlton, Australia, Immuron was formerly known as Anadis Limited before rebranding in December 2008.